faah

Dual FAAH/sEH-IN-1 is a dual inhibitor of sEH (soluble epoxide hydrolase) (IC50: 9.6 nM) and FAAH (fatty acid amide hydrolase) (IC50: 7 nM) with high affinity and anti-inflammatory activity.

FAAH inhibitor 1 (Benzothiazole analog 3) is a potent FAAH inhibitor with an IC50 of 18 nM.

CB2R/FAAH modulator-1, a cannabinoid type 2 receptor (CB2R) agonist, is also a fatty acid amide hydrolase (FAAH) inhibitor (IC50=4 μM) that reduces the production of pro-inflammatory and anti-inflammatory cytokines and is commonly used in inflammation studies. The Kis for CB2R and CB1R are 14.8 nM and 241.3 nM, respectively.

FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent inhibitor of FAAH (fatty acid amide hydrolase).

CB2R/FAAH modulator-2 (compound 26) is a dual modulator targeting CB2R and FAAH, acting as a CB2R agonist (Ki = 10.8 nM) and FAAH inhibitor (IC50 = 6.2 μM), with a Ki value of 152.9 nM for CB1R. It has research value in cancer, deleterious inflammatory cascades in neurodegenerative diseases, and COVID-19 infection.

CB2R/FAAH modulator-3 (compound 27) is a modulator targeting CB2R and FAAH, acting as a CB2R agonist with a Ki value of 20.1 nM and a CB1R agonist with a Ki value of 67.6 nM, while inhibiting FAAH with an IC50 value of 3.4 μM. This compound has research value in cancer, neurodegenerative disease-related inflammatory cascades, and COVID-19 infection.

MK-4409 is a novel and selective inhibitor of oxazole fatty acid amide hydrolase FAAH.MK-4409 can be used to study inflammatory and neuropathic pain.

MM-433593 is a selective fatty acid amide hydrolase (FAAH-1) inhibitor for the treatment of pain, inflammation, and other disorders.

Carprofen (Ridamyl) is a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities.

Biochanin A (4-Methylgenistein) is an isoflavone derivative isolated from red clover Trifolium pratense with anticarcinogenic properties. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor.

URB-597 (FAAH Inhibitor II) is an effective, orally bioavailable FAAH inhibitor (IC50: 4.6 nM), and no effect on other cannabinoid-related targets.

N-(3-Methoxybenzyl)Palmitamide is a promising FAAH inhibitor for the treatment of pain, inflammation, and CNS degenerative disorders.

Palmitoylisopropylamide is a selective FAAH inhibitor that inhibits [H]-AEA uptake and cell proliferation at low concentrations.

JNJ-1661010 (Takeda-25) is an effective and specific FAAH inhibitor (IC50: 10/ 12 nM for rat/human), shows >100-fold selectivity for FAAH-1 than FAAH-2.

BIA 10-2474 is a long-acting reversible inhibitor of fatty acid amide hydrolase (FAAH) that increases levels of the neurotransmitter anandamide in the central nervous system and in peripheral tissues (that is, the rest of the body other than the brain and spinal cord). BIA 10-2474(BIA10-2474) interacts with the human endocannabinoid system. BIA 10-2474(BIA10-2474) was in development for the treatment of a range of different medical conditions from anxiety to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, Y, hypertension or the treatment of obesity.

4-Nonylphenylboronic acid is a inhibitor of FAAH.

WWL 154 is an serine hydrolase (SH) and fatty acid amide hydrolase FAAH-4 inhibitor.

MAGL-IN-5 is a non-selective lipase inhibitor.

FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor with IC50 values of 145 nM for rat FAAH and 650 nM for human FAAH.

LY2183240 inhibits fatty acid amide hydrolase (FAAH) activity (IC50 = 12.4 nM). LY2183240 is a novel and highly effective blocker of anandamide uptake (IC50 = 270 pM).

PF 750 (ZINC27647189) is a selective and covalent inhibitor of FAAH. PF 750 shows IC50s varying from 16.2 to 595 nM in different incubation times.

SA 47 is a selective and effective inhibitor of fatty acid amide hydrolase (FAAH) and carbamate.

JZL195 is a selective and efficacious dual FAAH/MAGL inhibitor.

JNJ-40355003 is a specific fatty acid amide hydrolase (FAAH) inhibitor that increases plasma levels of fatty acid amides in rats, dogs, and crabs.